Trial
NCT04187508
A Study to Evaluate the Effect of AZD8154 Administered Via Nebulizer Once Daily in Subjects With Mild Allergic Asthma Challenged With an Inhaled Allergen
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
AstraZeneca
Collaborators
Parexel
Condition
Asthma
Intervention
AZD8154 nebulizer suspension, 20 mg/mL
Why stopped
The reason is: emerging pre-clinical toxicology findings.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-11-03